Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, has announced the accelerated availability and development of critical research tools to support the global scientific community in combating Nipah virus (NiV). This move comes in response to recent reports of NiV infections in West Bengal, India, which have reignited global concern and prompted public health authorities to prioritize research into this high-mortality pathogen.
Nipah virus, a member of the Paramyxoviridae family, is classified by the World Health Organization (WHO) as a priority pathogen due to its epidemic potential and high fatality rate, estimated between 40% to 75%. With no approved vaccines or specific antiviral treatments currently available, the demand for high-quality, biologically active reagents is critical for developing effective countermeasures.
To meet the urgent needs of researchers, Sino Biological has launched a series of high-purity NiV G and F proteins. These proteins are essential for understanding viral entry mechanisms and screening therapeutic antibodies. Additionally, the company is fast-tracking the development of NiV N proteins and pre-fusion and post-fusion F trimer proteins. The N proteins are based on the most recently reported strains, offering improved sequence relevance compared with existing products that contain multiple mutations. In addition to standard proteins, Sino Biological offers ProPure™ endotoxin-free (ET-free) versions of NiV G and F proteins, designed for vaccine research applications where immunogen purity and endotoxin control are critical.
“Our mission is to provide the scientific community with the highest quality tools as rapidly as possible when emerging infectious diseases threaten global health,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. “By expanding our NiV portfolio, we aim to empower researchers to streamline vaccine discovery and diagnostic breakthroughs.”
The expansion of Sino Biological’s NiV reagent portfolio underscores the company’s commitment to supporting global health. Researchers can access these new tools through the company’s website, including dedicated pages for Nipah virus research and NiV proteins and reagents. These resources are designed to accelerate the development of vaccines and diagnostics, which are urgently needed to combat this deadly virus.
The implications of this announcement are significant for the global scientific community. By providing high-quality, biologically active reagents that are sequence-relevant to current circulating strains, Sino Biological is enabling researchers to conduct more accurate and effective studies. This could expedite the development of countermeasures against Nipah virus, potentially saving lives in future outbreaks. The company’s focus on endotoxin-free proteins also addresses a critical need in vaccine research, where purity is paramount.
As the world continues to face emerging infectious diseases, the availability of such research tools becomes increasingly important. Sino Biological’s proactive approach in expanding its NiV portfolio demonstrates the role that biotechnology companies can play in pandemic preparedness. With these tools, researchers are better equipped to understand the virus, screen potential therapeutics, and develop vaccines that could prevent the next outbreak.
